The primary amino acid sequences of the mutated peptides with variants at the eighth residue were listed with the inhibition rate at a fixed concentration of 1 μM. Those with > 90% inhibition were further characterized for IC50
Name
Amino acid sequence
Inhibition (%)
IC50 ± SD (nM)
BCP-16B
Ala-Cys-Ala-Gly-Arg-Cys-Gly-Ser-Ala-Cys-Leu
95.8%
116.67 ± 7.79 nM
BCP-24B
Ala-Cys-Ala-Gly-Arg-Cys-Gly-Lys-Ala-Cys-Leu
98.8%
80.56 ± 3.86 nM
BCP-25B
Ala-Cys-Ala-Gly-Arg-Cys-Gly-His-Ala-Cys-Leu
100.0%
57.78 ± 2.83 nM
BCP-26B
Ala-Cys-Ala-Gly-Arg-Cys-Gly-Glu-Ala-Cys-Leu
88.8%
-
BCP-27B
Ala-Cys-Ala-Gly-Arg-Cys-Gly-Gln-Ala-Cys-Leu
100.0%
57.09 ± 4.79 nM
BCP-28B
Ala-Cys-Ala-Gly-Arg-Cys-Gly-Tyr-Ala-Cys-Leu
100.0%
92.74 ± 14.33 nM
BCP-29B
Ala-Cys-Ala-Gly-Arg-Cys-Gly-Thr-Ala-Cys-Leu
100.0%
48.16 ± 6.28 nM
BCP-30B
Ala-Cys-Ala-Gly-Arg-Cys-Gly-Trp-Ala-Cys-Leu
100.0%
78.01 ± 4.70 nM
BCP-31B
Ala-Cys-Ala-Gly-Arg-Cys-Gly-Met-Ala-Cys-Leu
98.1%
118.39 ± 17.34 nM
BCP-32B
Ala-Cys-Ala-Gly-Arg-Cys-Gly-Leu-Ala-Cys-Leu
100.0%
40.46 ± 6.35 nM
BCP-33B
Ala-Cys-Ala-Gly-Arg-Cys-Gly-Ile-Ala-Cys-Leu
100.0%
48.17 ± 3.69 nM
BCP-34B
Ala-Cys-Ala-Gly-Arg-Cys-Gly-Phe-Ala-Cys-Leu
98.3%
107.82 ± 11.47 nM
BCP-35B
Ala-Cys-Ala-Gly-Arg-Cys-Gly-Val-Ala-Cys-Leu
86.9%
-
BCP-36B
Ala-Cys-Ala-Gly-Arg-Cys-Gly-hLeu-Ala-Cys-Leu
98.6%
90.77 ± 7.41 nM
-: no data. SD: standard deviation; IC50: half-maximal inhibitory concentration
We acknowledge the instrument facility of the Biotech Drug Research Center for providing support with mass spectrometry, protein expression, and plate reader. We also acknowledge the institutional center for Shared Technologies and Facilities of SIMM for providing services including NMR and MS data recording.
Author contributions
QW: Conceptualization, Validation, Formal analysis, Investigation, Data curation, Writing—original draft. YW and JL: Conceptualization, Data curation, Supervision. HL and SC: Conceptualization, Resources, Supervision, Writing—original draft, Writing—review & editing, Project administration, Funding acquisition, Resources. All authors read and approved the submitted version.
Conflicts of interest
The authors declare that they have no conflicts of interest.
Ethical approval
Not applicable.
Consent to participate
Not applicable.
Consent to publication
Not applicable.
Availability of data and materials
The raw data supporting the conclusions of this manuscript will be made available by the corresponding author, without undue restriction, to any qualified researcher upon request.
Funding
This study was supported by the Distinguished Young Scholars Program and the General Program of the National Natural Science Foundation of China (#22477128) awarded to SC. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Li J, Lai S, Gao GF, Shi W. The emergence, genomic diversity and global spread of SARS-CoV-2.Nature. 2021;600:408–18. [DOI] [PubMed]
Beladiya J, Kumar A, Vasava Y, Parmar K, Patel D, Patel S, et al. Safety and efficacy of COVID-19 vaccines: A systematic review and meta-analysis of controlled and randomized clinical trials.Rev Med Virol. 2024;34:e2507. [DOI] [PubMed]
Chan JF, Yuan S, Chu H, Sridhar S, Yuen K. COVID-19 drug discovery and treatment options.Nat Rev Microbiol. 2024;22:391–407. [DOI] [PubMed]
Li G, Hilgenfeld R, Whitley R, Clercq ED. Therapeutic strategies for COVID-19: progress and lessons learned.Nat Rev Drug Discov. 2023;22:449–75. [DOI] [PubMed] [PMC]
Flores-Vega VR, Monroy-Molina JV, Jiménez-Hernández LE, Torres AG, Santos-Preciado JI, Rosales-Reyes R. SARS-CoV-2: Evolution and Emergence of New Viral Variants.Viruses. 2022;14:653. [DOI] [PubMed] [PMC]
Markov PV, Ghafari M, Beer M, Lythgoe K, Simmonds P, Stilianakis NI, et al. The evolution of SARS-CoV-2.Nat Rev Microbiol. 2023;21:361–79. [DOI] [PubMed]
Zhao Y, Zhu Y, Liu X, Jin Z, Duan Y, Zhang Q, et al. Structural basis for replicase polyprotein cleavage and substrate specificity of main protease from SARS-CoV-2.Proc Natl Acad Sci U S A. 2022;119:e2117142119. [DOI] [PubMed] [PMC]
Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors.Nature. 2020;582:289–93. [DOI] [PubMed]
Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs.Science. 2003;300:1763–7. [DOI] [PubMed]
Amorim VMdF, Soares EP, Ferrari ASdA, Merighi DGS, Souza RFd, Guzzo CR, et al. 3-Chymotrypsin-like Protease (3CLpro) of SARS-CoV-2: Validation as a Molecular Target, Proposal of a Novel Catalytic Mechanism, and Inhibitors in Preclinical and Clinical Trials.Viruses. 2024;16:844. [DOI] [PubMed] [PMC]
Wang H, He S, Deng W, Zhang Y, Li G, Sun J, et al. Comprehensive Insights into the Catalytic Mechanism of Middle East Respiratory Syndrome 3C-Like Protease and Severe Acute Respiratory Syndrome 3C-Like Protease.ACS Catal. 2020;10:5871–90. [DOI] [PubMed]
Monica GL, Bono A, Lauria A, Martorana A. Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure-Activity Relationship Insights and Evolution Perspectives.J Med Chem. 2022;65:12500–34. [DOI] [PubMed] [PMC]
Liu Y, Liang C, Xin L, Ren X, Tian L, Ju X, et al. The development of Coronavirus 3C-Like protease (3CLpro) inhibitors from 2010 to 2020.Eur J Med Chem. 2020;206:112711. [DOI] [PubMed] [PMC]
Chen R, Gao Y, Liu H, Li H, Chen W, Ma J. Advances in research on 3C-like protease (3CLpro) inhibitors against SARS-CoV-2 since 2020.RSC Med Chem. 2022;14:9–21. [DOI] [PubMed] [PMC]
Bai B, Arutyunova E, Khan MB, Lu J, Joyce MA, Saffran HA, et al. Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors.RSC Med Chem. 2021;12:1722–30. [DOI] [PubMed] [PMC]
Bai B, Belovodskiy A, Hena M, Kandadai AS, Joyce MA, Saffran HA, et al. Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and in Vitro Biological Stability.J Med Chem. 2022;65:2905–25. [DOI] [PubMed]
Dai W, Zhang B, Jiang X, Su H, Li J, Zhao Y, et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease.Science. 2020;368:1331–5. [DOI] [PubMed] [PMC]
Dai W, Jochmans D, Xie H, Yang H, Li J, Su H, et al. Design, Synthesis, and Biological Evaluation of Peptidomimetic Aldehydes as Broad-Spectrum Inhibitors against Enterovirus and SARS-CoV-2.J Med Chem. 2022;65:2794–808. [DOI] [PubMed]
Ahmadi R, Emami S. Recent applications of vinyl sulfone motif in drug design and discovery.Eur J Med Chem. 2022;234:114255. [DOI] [PubMed]
Meadows DC, Gervay-Hague J. Vinyl sulfones: synthetic preparations and medicinal chemistry applications.Med Res Rev. 2006;26:793–814. [DOI] [PubMed]
Xiao Y, Chen F. The vinyl sulfone motif as a structural unit for novel drug design and discovery.Expert Opin Drug Discov. 2024;19:239–51. [DOI] [PubMed]
Ollis DL, Cheah E, Cygler M, Dijkstra B, Frolow F, Franken SM, et al. The alpha/beta hydrolase fold.Protein Eng. 1992;5:197–211. [DOI] [PubMed]
Günther S, Reinke PYA, Fernández-García Y, Lieske J, Lane TJ, Ginn HM, et al. X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease.Science. 2021;372:642–6. [DOI] [PubMed] [PMC]
Chen S, Bertoldo D, Angelini A, Pojer F, Heinis C. Peptide ligands stabilized by small molecules.Angew Chem Int Ed Engl. 2014;53:1602–6. [DOI] [PubMed]
Jiang X, Su H, Shang W, Zhou F, Zhang Y, Zhao W, et al. Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir.Nat Commun. 2023;14:6463. [DOI] [PubMed] [PMC]
Chuck C, Chong L, Chen C, Chow H, Wan DC, Wong K. Profiling of substrate specificity of SARS-CoV 3CL.PLoS One. 2010;5:e13197. [DOI] [PubMed] [PMC]
Shaqra AM, Zvornicanin SN, Huang QYJ, Lockbaum GJ, Knapp M, Tandeske L, et al. Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance.Nat Commun. 2022;13:3556. [DOI] [PubMed] [PMC]
Kneller DW, Galanie S, Phillips G, O'Neill HM, Coates L, Kovalevsky A. Malleability of the SARS-CoV-2 3CL Mpro Active-Site Cavity Facilitates Binding of Clinical Antivirals.Structure. 2020;28:1313–20.e3. [DOI] [PubMed] [PMC]
Lee J, Kenward C, Worrall LJ, Vuckovic M, Gentile F, Ton A, et al. X-ray crystallographic characterization of the SARS-CoV-2 main protease polyprotein cleavage sites essential for viral processing and maturation.Nat Commun. 2022;13:5196. [DOI] [PubMed] [PMC]
Xing Y, Zhang H, Wang Y, Zong Z, Bogyo M, Chen S. DNA encoded peptide library for SARS-CoV-2 3CL protease covalent inhibitor discovery and profiling.RSC Chem Biol. 2024;5:691–702. [DOI] [PubMed] [PMC]
Chen S, Lovell S, Lee S, Fellner M, Mace PD, Bogyo M. Identification of highly selective covalent inhibitors by phage display.Nat Biotechnol. 2021;39:490–8. [DOI] [PubMed] [PMC]
Iskandar SE, Chiou LF, Leisner TM, Shell DJ, Norris-Drouin JL, Vaziri C, et al. Identification of Covalent Cyclic Peptide Inhibitors in mRNA Display.J Am Chem Soc. 2023;145:15065–70. [DOI] [PubMed] [PMC]
Jiang L, Liu S, Jia X, Gong Q, Wen X, Lu W, et al. ABPP-CoDEL: Activity-Based Proteome Profiling-Guided Discovery of Tyrosine-Targeting Covalent Inhibitors from DNA-Encoded Libraries.J Am Chem Soc. 2023;145:25283–92. [DOI] [PubMed]
